MabThera (rituximab)

Information on this site is not intended as medical advice and should not be used as a substitute for consulting with qualified doctor.

Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation that leads to stiff, swollen and painful joints. This ultimately results in irreversible joint damage and disability. MabThera selectively targets B-cells and represents a new highly effective therapeutic approach for RA in addition to existing treatments such as DMARDs and TNF-inhibitors.1

 

In Bangladesh MabThera is approved for the following indications.2

  • Rheumatoid Arthritis

MabThera IV in combination with methotrexate is indicated in adult patients for:

-- the treatment of moderate to severe, active rheumatoid arthritis (RA) when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.

-- treatment of moderate to severe, active rheumatoid arthritis in patients with an inadequate response or intolerance to one or more tumour necrosis factor (TNF) inhibitor therapies.

  • MabThera IV has been shown to reduce the rate of progression of joint damage as measured by X-ray, to improve physical function and to induce major clinical response, when given in combination with methotrexate.
  • Granulomatosis with polyangiitis (Wegener’s) (GPA) and Microscopic Polyangiitis (MPA)

MabThera IV in combination with glucocorticoids is indicated for the treatment of patients with severely active GPA, also known as Wegener’s granulomatosis, and MPA.

 

For more disease and medicine related queries you may discuss with your physician.

 

In Bangladesh MabThera is available as

IV

  • Vial of 100 mg/10 ml
  • Vial of 500 mg/50 ml

 

References

1. Global Website: Investors. MabThera inhibits the destruction of joints in patients with early rheumatoid arthritis. (2008, December 19). [Internet; cited 2018, November 25]. Retrieved from https://www.roche.com/investors/updates/inv-update-2008-12-19.htm

2. MabThera Product Information _ FE-English Ro 45-2294 _ July 2016